Expert Interview
Looking at Current and Emerging Therapies for Hepatitis B (HBV)
Ticker(s): DTIL, GILD, BMY, GSK, MRKInstitution: Kings College London
- Consultant Hepatologist and Transplant Physician at King’s College Hospital, leading the Regional Hepatitis Program and serving as Clinical Director for the South London NIHR Clinical Research Network.
- Manages and treats 20+ patients for Hepatitis B per year
- Has performed extensive research on viral hepatitis, liver transplantation, and novel therapies, contributing to over 100 peer-reviewed publications.
How do current antiviral therapies like tenofovir and entecavir compare to emerging RNAi therapies like fazirsiran in achieving sustained HBsAg loss for HBV patients?
Added By: max_adminWhat are the main barriers to achieving a functional cure for chronic HBV, and how might combination therapies address these challenges?
Added By: max_adminWhat emerging therapies for HepB are most exciting for you?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
